Recognizing the Role of Capmatinib for METex14 in NSCLC

Host: Jacob Sands, MD Guest: Edward B. Garon, MD, MS Recently approved capmatinib may be a new treatment for patients with metastatic non-small cell lung cancer who have MET exon 14 skipping mutations. To learn more about this emerging treatment option, Dr. Jacob Sands speaks with Dr. Edward Garon from the David Geffen School of Medicine at the University of California in Los Angeles to explore data from the GEOMETRY Mono-1 study.